{"id":"insulin-glulisine-hmr1964","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_fixedAt":"2026-03-30T14:19:40.098861","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glulisine is a recombinant human insulin analog engineered with amino acid substitutions (lysine at position B3 and glutamic acid at position B29) to accelerate absorption and onset of action compared to regular human insulin. It binds to insulin receptors on muscle and adipose tissue, promoting glucose uptake and storage while suppressing hepatic glucose production, thereby lowering blood glucose levels in diabetic patients.","oneSentence":"Insulin glulisine is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:15.744Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT03529123","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-19","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT01768559","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-01","conditions":"Type 2 Diabetes","enrollment":894},{"nctId":"NCT01234597","phase":"PHASE4","title":"Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-12","conditions":"Diabetes Mellitus, Type 2","enrollment":219},{"nctId":"NCT00964574","phase":"PHASE4","title":"Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 1","enrollment":68},{"nctId":"NCT00290043","phase":"PHASE1","title":"Glulisine Pre- and Postmeal","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-12","conditions":"Diabetes Mellitus Type 1","enrollment":20},{"nctId":"NCT00545337","phase":"PHASE3","title":"Glulisine + Lantus in Type I Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT00290979","phase":"PHASE3","title":"Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-12","conditions":"Diabetes Mellitus, Type 1","enrollment":250},{"nctId":"NCT00290927","phase":"PHASE3","title":"Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-12","conditions":"Diabetes Mellitus, Type 2","enrollment":390},{"nctId":"NCT00546702","phase":"PHASE3","title":"Glulisine + Lantus in Type I Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 1","enrollment":142},{"nctId":"NCT00489190","phase":"PHASE4","title":"APIDRA Registration Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-08","conditions":"Diabetes Mellitus, Type 1","enrollment":45},{"nctId":"NCT00046150","phase":"PHASE3","title":"12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-05","conditions":"Diabetes, Type I","enrollment":59},{"nctId":"NCT00368394","phase":"PHASE1","title":"Dose-Exposure-Response in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-01","conditions":"Diabetes Mellitus, Type I","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2005 Sep","pmid":"16052329","title":"Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors.","journal":"Diabetologia"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Apidra"],"phase":"marketed","status":"active","brandName":"INSULIN GLULISINE (HMR1964)","genericName":"INSULIN GLULISINE (HMR1964)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glulisine is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}